Guardant Health, Inc. (NASDAQ:GH) Receives $129.00 Average Target Price from Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have been assigned an average rating of “Moderate Buy” from the twenty-one analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and nineteen have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $129.7895.

A number of equities analysts have recently weighed in on GH shares. Wells Fargo & Company lifted their price target on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Citigroup raised their price objective on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Barclays lifted their target price on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Robert W. Baird assumed coverage on Guardant Health in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 target price for the company. Finally, Stifel Nicolaus increased their price target on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 20th.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $129.69 on Monday. Guardant Health has a 52-week low of $38.03 and a 52-week high of $133.97. The stock has a market cap of $17.20 billion, a P/E ratio of -38.26 and a beta of 1.61. The firm has a 50 day moving average price of $95.08 and a 200 day moving average price of $99.96.

Insiders Place Their Bets

In other Guardant Health news, insider Terilyn J. Monroe sold 3,832 shares of Guardant Health stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $92.68, for a total value of $355,149.76. Following the transaction, the insider owned 20,990 shares of the company’s stock, valued at approximately $1,945,353.20. The trade was a 15.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Chris Freeman sold 24,406 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the completion of the transaction, the insider owned 60,034 shares of the company’s stock, valued at $7,124,234.78. This trade represents a 28.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 332,244 shares of company stock worth $36,156,026 in the last three months. 5.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Guardant Health

A number of hedge funds and other institutional investors have recently made changes to their positions in GH. V Square Quantitative Management LLC acquired a new position in Guardant Health in the 4th quarter worth $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health during the 4th quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health in the 4th quarter valued at about $31,000. Elyxium Wealth LLC bought a new stake in shares of Guardant Health in the fourth quarter valued at about $35,000. Finally, Parallel Advisors LLC lifted its holdings in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.